Abstract:Background: Little is known about the biweekly combined use of cetuximab and chemotherapy as second line treatment of metastatic colorectal cancer (mCRC). Recently, DNA methylation status has been reported to be a new possible predictor of the efficacy from the anti-epidermal growth factor receptor (EGFR) antibody treatment. The purpose of this study was to examine the efficacy and safety of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as a second-line treatment for KRAS exon 2 wild-type mCRC. We also investigated the predictability of DNA methylation status on the efficacy of the EGFR antibody-containing treatment. Methods: Patients who were refractory or intolerant to the first-line chemotherapy were enrolled and received biweekly cetuximab plus mFOLFOX6 or mFOLFIRI. The primary endpoint was progression free survival (PFS). Tumor evaluations were performed every 2 months using Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. DNA methylation status of colorectal cancer cells was defined by a modified MethyLight assay.Results: Sixty-six cases were enrolled. The median PFS (mPFS) was 5.1 [95% confidence interval (CI), 3.8-7.6] months. The median overall survival (mOS) was 12.7 (95% CI, 7.5-15.3) months. Grade 3 or higher neutropenia occurred in 53.0% of patients, whereas skin disorders with a grade 3 or higher occurred in <15% of patients. In multivariate analysis, DNA methylation status could not be an independent predictor of PFS [hazard ratio (HR), 1.43; P=0.39] and OS (HR, 2.13; P=0.086). However, in RAS/BRAF wild-type patients, the mPFS and mOS in the low-methylated colorectal cancer (LMCC) group was numerically better than those in the highly-methylated colorectal cancer (HMCC) group, although the difference was not statistically significant [mPFS: 8.5 (95% CI, 6.1-10.9) vs. 3.3 (95% CI, 1.2-not reached) months, P=0.79; Delta mPFS, 5.2 months; mOS: 15.3 (95% CI, 11.9-23.5) vs. 6.5 (95% CI, 3.1-not reached) months, P=0.53; Delta mOS, 8.8 months].Conclusions: Biweekly cetuximab plus mFOLFOX6 or mFOLFIRI is a useful second-line therapy for mCRC. DNA methylation status warrants further exploration as a predictive biomarker for anti-EGFR efficacy in mCRC.

Phase Ii Trial Of Cetuxirnab Plus Irinotecan For Oxaliplatin- And Irinotecan-Based Chemotherapy-Refractory Patients With Advanced And/Or Metastatic Colorectal Cancer: Evaluation Of Efficacy And Safety Based On Kras Mutation Status (T-Core0801)

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

Phase Ii Trial of Cetuximab (cmab) Plus Irinotecan (Cpt-11) for Chemorefractory Japanese Patients with Advanced And/Or Metastatic Colorectal Cancer (mcrc), to Evaluate the Efficacy and Safety Based on Kras, Braf, Pik3ca, Nras, and Akt1 Mutation Status (T-Core0801)

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

Efficacy and Safety of IBI351 (GFH925) Monotherapy in Metastatic Colorectal Cancer Harboring KRASG12C Mutation: Preliminary Results from a Pooled Analysis of Two Phase I Studies.

A KRAS Mutation Status-Stratified Randomized Phase II Trial of Gemcitabine and Oxaliplatin Alone or in Combination with Cetuximab in Advanced Biliary Tract Cancer.

Phase II Study of Biweekly Cetuximab Plus Mfolfox6 or Mfolfiri As Second-Line Treatment for Metastatic Colorectal Cancer and Exploratory Analysis of Associations Between DNA Methylation Status and the Efficacy of the Anti-Egfr Antibody: T-CORE1201

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer

Cetuximab Plus Irinotecan in Treatment of Metastatic Colorectal Cancer

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

Efficacy Of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy And Its Effects On K-Ras Mutations In Advanced Colorectal Cancer

[Effect of KRAS Mutation on Efficacy of Cetuximab Combined with Chemotherapy in Advanced Colorectal Cancer Patients].

Impact Ofkrasmutation and PTEN Expression on Cetuximab-Treated Colorectal Cancer

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17

Phase II Study of S-1 Plus Leucovorin (1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China: Comparing Results of Each Country and Updating Overall Survival

Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C -mutated colorectal cancer: a phase 1b trial

A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type <i>K-ras</i> metastatic colorectal cancer patients.

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)